Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival.
Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood-brain barrier and control metastatic foci. However, this problem may be overcome by new active drugs such as cabazitaxel.
Written by:
Caffo O, Veccia A, Russo L, Galligioni E. Are you the author?
Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38100 Trento, Italy.
Reference: Future Oncol. 2012 Dec;8(12):1585-95.
doi: 10.2217/fon.12.156
PubMed Abstract
PMID: 23231520
UroToday.com Prostate Cancer Section
